Podcast appearances and mentions of philip marsden

Beijing has vowed to “fight to the end” if Donald Trump follows through on his threat to increase tariffs, so is a full-blown trade war between the two superpowers inevitable? Journalist Tessa Szyszkowitz and Monocle’s Christopher Lord discuss this and whether or not Europe is ready to accept the brain drain from the US. Plus: is Emmanuel Macron positioning himself to become the de facto leader of Europe and are we really seeing species brought back from extinction? We also hear from Philip Marsden about his new book, ‘Under a Metal Sky: A Journey Through Rocks’.See omnystudio.com/listener for privacy information.

My guest in this week's Book Club podcast is Philip Marsden, whose new book Under A Metal Sky: A Journey Through Minerals, Greed and Wonder looks in thrilling and surprising detail at the wonders that are to be found beneath our feet. On the podcast he takes me through the meanings that rocks and metals have had through human history, from the bronze age, via the alchemist's quest for the philosopher's stone, to the present day.

My guest in this week's Book Club podcast is Philip Marsden, whose new book Under A Metal Sky: A Journey Through Minerals, Greed and Wonder looks in thrilling and surprising detail at the wonders that are to be found beneath our feet. On the podcast he takes me through the meanings that rocks and metals have had through human history, from the bronze age, via the alchemist's quest for the philosopher's stone, to the present day.

Have you ever wondered how to make money with a home studio? Maybe you're seeking answers to the questions: How do I market my home studio? How do I get more clients with my recording studio? How do you differentiate yourself from your competitors? Or maybe even, how do I acquire and keep clients? Then check out EP 148 of the Inside The Mix podcast.Want to unlock the secrets to building a profitable home studio? Join us as I uncover essential tips with Philip Marsden of Marsden Mastering, from acquiring clients to creating a robust portfolio and working with musicians you admire. Learn how to set your rates, position yourself in the market, and identify your target audience while maintaining strong client relationships. Philip also shares his top revision strategy, guaranteeing client satisfaction and long-term success.Have you ever wondered how to stand out in a crowded marketplace? Discover how consistency and relationship-building can make you memorable in the creative industry. Philip emphasises the importance of unique service offerings and clear communication. By delivering projects on time, being approachable, and being receptive to feedback, you can foster trust and become a preferred choice in music production and engineering. We'll provide practical tips to help you stand out in a competitive field.Effective client communication and satisfaction are crucial to your success. Learn to convey the transformation you offer, manage client feedback, and set clear expectations. Philip discusses the value of written communication, tailored proposals, and understanding clients' deeper goals. We also touch on recognising when a service relationship isn't a good fit and the benefits of offering refunds. Finally, get introduced to Philip's podcast, "The Savvy Producer," which offers actionable advice on productivity and efficiency in the music industry. Join us for invaluable insights into creating a profitable home studio and building lasting client relationships.CLICK HERE to follow Philip: https://marsdenmastering.com/Send me a Message Support the Show.► ► ► WAYS TO CONNECT ► ► ► Grab your FREE Producer Growth Scorecard TODAY!✸✸✸✸✸✸✸✸✸✸✸✸✸✸✸✸✸✸✸✸✸✸✸✸✸✸Are you READY to take on the 28-day challenge and release more music? Bag your FREE Producer Growth Scorecard at Synth Music Mastering: https://www.synthmusicmastering.com/scorecardSend a DM via IG @insidethemicpodcastEmail me at marc@synthmusicmastering.com

Emperor Tewodros II is one of the towering figures of modern Ethiopian history. He tried to unify and modernise Ethiopia but his reign was also marked by brutality. He faced a rising tide of rebellion inside the country and then in 1868 a British military expedition marched into the Ethiopian highlands. Its aim was to free British diplomatic envoys the Emperor had imprisoned. Tewodros II made a last stand at Magdala, his mountain top fortress. In 2016, Rob Walker spoke to historian Philip Marsden. (Picture: Tewodros II. Credit: Getty Images)

Dr Philip Marsden is a Professor of Law and Economics, an ultra-marathon runner, an antitrust rapper and a co-author of the Furman report into digital competition, and he joins us to talk about all these things and more. Plus everything that's happened since the last episode: regulations, consultations, user locations, triangulations, revised variations, and artificial intelligence gets fast and furious. All this and more with co-hosts Moya Dodd and Matt Rubinstein of The Competitive Edge with Gilbert + Tobin.   Treasury consultation on Digital Platform Regulatory Reform Jeremy Jose on the gas price cap in the Australian Financial Review ACCC consultation on the NBN Revised Variation to the Special Access Undertaking All 25 of Claude's absurd Fast & Furious movie titles Digital Competition Expert Panel, Unlocking Digital Competition ft. Dr Philip Marsden Dr Philip Marsden's original antitrust rap. Meet the Gilbert + Tobin Competition + Regulation team Email us at edge@gtlaw.com.au See omnystudio.com/listener for privacy information.

At the end of June 2022, the yearly conference of the Academic Society for Competition Law (ASCOLA) took place in Porto. In between panels of what is perhaps the most important antitrust conference of the year, Kay and Friso caught up with some fellow academics. They talked with Magali Eben about collegiality in the competition law community, with Francesco Ducci about his award-winning paper on randomization as an antitrust remedy, with Rupprecht Podszun about what makes the EU such an exciting place for competition law scholarship, and with Philip Marsden about the importance of antitrust policy for people today. Let us know what you think, by engaging with MONOPOLY ATTACK on Twitter (@MonopolyAttack) and LinkedIn Learn more about the hosts: Kay Jebelli, Counsel to the Computer & Communications Industry Association - Twitter (@KayJebelli), LinkedIn, SSRN Friso Bostoen, Academic at KU Leuven & Research Foundation Flanders - Twitter (@BostoenFriso), LinkedIn, SSRN Further reading: For another perspective on this year's ASCOLA Conference, we recommend Rupprecht Podszun's debriefing on the D'Kart Blog. Philip Marsden's previous antitrust rap is available on YouTube. Francesco Ducci's paper “Randomization as an Antitrust Remedy” is available here. If you'd like to know more about ASCOLA, check out the website and blog here.

Two stories about power – and how it can be abused. The first is the tale of an MP caught looking at porn in the House of Commons and what it might tell us about the culture of political reporting at Westminster. The other is the joint BBC and The Guardian investigation into alleged sexual misconduct by the DJ Tim Westwood. Also in the programme, the future of tech regulation in the UK. Guests: Chi Chi Izundu, Reporter on "Tim Westwood: Abuse of Power", Katie Ferguson, Deputy Political Editor at The Sun, Eleanor Langford, Political Reporter at Politics Home, Margot James, former government minister, Philip Marsden, Professor of Law and Economics at the College of Europe and Kate Beioley, Legal Correspondent at the Financial Times. Presenter: Katie Razzall Sound engineer: Duncan Hannant Producer: Helen Fitzhenry

9 March, 2022 - Prof. Philip Marsden, opens the debate with his thoughts on how administrative decision-making procedures should bolster before the waves of digital infringement cases arrive.

On The Alfred Daily Today: Work to prevent Motcombe flooding is top priority. Shaftesbury students impress during debate night. Storm Eustice latest. Shaftesbury councillors asked to renew £10k tourism promotion. Shaftesbury's ‘hottest' house sale areas – Matt Boatwright. Meet Shaftesbury Book Festival speaker Philip Marsden. Shaftesbury what's ons. Something for the weekend - events worth driving to. Shaftesbury Wellness Shark Laura Langley on doughnuts. Soundscapes- a little owl in Fontmell

Boss ladies unite in this celebration of inspiringand empowered female athletes from around theworld. From Australian legends Sam Kerr, Ash Bartyand Ariarne Titmus to international superstarslike Ruby Tui, Simone Biles, Naomi Osaka and theWilliams sisters, these boss ladies are at the top oftheir games, both on and off the field.Every boss lady was once a little kid with a hugedream. Let their trials and triumphs inspire youto work hard at what you love and to believe inyourself, no matter whether you win or lose.  PHILLIP MARSDEN is a Sydney-based full-time illustratorfrom Liverpool, England. He is a regular contributor tomagazines such as Kerrang, NME and Elle, has illustratedbooks such as Kicking Goals by Adam Goodes, I Can'tRemember the Title But the Cover Is Blue by Elias Greig,A Boy Called Bob by Bob Murphy & Tony Wilson and AFooty Girl's Guide to the Stars of 2017 by Nicole Hayesand Alicia Sometimes. Phillip regularly hosts drawingworkshops for kids.   Luke and Phillip talk about amazing female athletes, Liverpool, and stick men art. See omnystudio.com/listener for privacy information.

A keen “day sailor” since boyhood, Philip Marsden had long been entranced by the mystical lure of the Summer Isles since long distant visits to an inspirational aunt who made a life and mysteriously died on one of them. His latest book, The Summer Isles tells how, with beguilingly insane bravado, he buys a clinker-built yacht and sails from his home in South Cornwall up the west coast to revisit them. Marsden, being a polymath as well as sailor, his occasionally hair-raising adventures along the way are spiced with the histories and myths of the fascinating places he visits. This was the closing event of North Cornwall Book Festival 2021.

This week's episode features author Shih-Chuan Chou and editorialist Alexander Sandhu discuss the article "Impact of High-Deductible Health Plans on Emergency Department Patients With Nonspecific Chest Pain and Their Subsequent Care." Dr. Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the Journal and its editors. We are your co-hosts, I'm Dr. Carolyn Lam Associate Editor from the National Heart Center and Duke National University of Singapore. Dr. Greg Hundley: And I'm Dr. Greg Hundley Associate Editor, Director of the Pauley Heart center at VCU health in Richmond, Virginia. Dr. Carolyn Lam: Greg, I am so excited about today's feature discussion that's going to be about high deductible health plans and their impact on emergency department patients with chest pain and their subsequent care. Now, I can tell you as coming from outside of US, I learned so much from this discussion so everybody's going to want to hear it. But before we go there, let's discuss the other papers in today's issue. Greg, do you have a paper? Dr. Greg Hundley: You bet. Thanks Carolyn. So my paper is going to really evaluate a very interesting question about the role of measuring lipoproteins and their subfractions in patients, not with coronary disease, but peripheral arterial disease. And it comes to us from Dr. Scott Damrauer from the University of Pennsylvania School of Medicine. So Carolyn lipoprotein related traits have been consistently identified as risk factors for atherosclerotic cardiovascular disease, just like we said. Largely based on their role in progression of coronary artery disease, but the relative contributions of these lipoproteins to those with peripheral arterial disease really haven't been as well defined. So these authors leveraged a large scale genetic association data to investigate the effects of circulating lipoprotein related traits on peripheral arterial disease risk. Dr. Carolyn Lam: Interesting. So what did they find, Greg? Dr. Greg Hundley: Right, Carolyn. So ApoB was prioritized as the major lipoprotein fraction usually or almost causally responsible for both peripheral and coronary artery disease risk. Extra small VLDL particle concentration, we'll call that excess VLDLP was identified as the most likely subfraction associated with peripheral arterial disease risk while large LDL particle concentration was most likely the sub fraction associated with coronary artery disease risk. And genes associated with excess VLDLP and large LDL particle concentration included canonical ApoB pathway components although gene specific effects were quite variable. And then finally Carolyn, lipoprotein A was associated with increased risk of peripheral arterial disease, independent of Apo protein B. So therefore Carolyn, I think the take home message from this study is that ApoB lowering drug targets and ApoB containing lipoprotein subfractions had really diverse associations with atherosclerotic cardiovascular disease and distinct subfraction associated genes suggested that possible differences in the role of these lipoproteins really are involved in the pathogenesis of peripheral arterial as opposed to coronary arterial disease.   Dr. Carolyn Lam: Wow. Thanks Greg. Hey, it struck me that we haven't had a quiz in a long time. Okay, but we're not going to do it now. Don't choke because this one's kind of tough. I don't think I could even answer it. What is phospholamban? Dr. Greg Hundley: Well, let me guess. I remember having this, I think. Let's just... Carolyn I do not know what phospholamban is. Dr. Carolyn Lam: Let me just tell us all. Phospholamban is a critical regulator of calcium cycling and contractility in the heart. The loss of arginine at position 14 in phosphate lanvin is associated with dilated cardiomyopathy and a high prevalence of ventricular arrhythmias. But how this deletion causes dilated cardiomyopathy is still poorly understood. And there are no disease specific therapies. And hence today's paper, which comes from Dr. Karakikes and colleagues from Stanford university school of medicine. What they did is they employed human induced pluripotent stem cells and CRISPR Cas9 gene editing technologies to create an in vitro model of dilated cardiomyopathy associated with this phosphate lanvin 14 deletion mutation. Single cell RNA sequencing revealed the activation of an unfolded protein response pathway, which was also evident by significant up-regulation of marker genes in the hearts of patients with the deletion. Pharmacological and molecular modulation of this unfolded protein response pathways suggest a compensatory role in this type of dilated cardiomyopathy. Augmentation of the unfolded protein response by the small molecule BIP protein inducer X Millia rated contractile dysfunction. Dr. Greg Hundley: So Carolyn, tell me what are the clinical implications? Dr. Carolyn Lam: Well, these findings suggest a mechanistic link between proteostasis and the phospholamban 14 deletion induce pathophysiology that could be exploited to develop a therapeutic strategy for this kind of cardiomyopathy. The study also highlights how human induced pluripotent stem cells and cardiomyocyte modeling could be combined with small molecule testing as a paradigm for studying genotype, phenotype associations in heart disease. Dr. Greg Hundley: Very nice Carolyn. Well, my next paper comes to us also from the world of preclinical science. And it's from Dr. Philip Marsden from the University of Toronto. And Carolyn endothelial nitric oxide synthase or eNOS is an endothelial cell specific gene predominantly expressed in medium to large size arteries where endothelial cells experience athero-protective laminar flow with high shear stress. Now disturbed flow with lower average shear stress decreases eNOS transcription, which leads to the development of atherosclerosis especially at bifurcations and in the curvatures of arteries. So the prototypical arterial endothelial cell gene contains two distinct flow responsive SIS DNA elements in the promoter. The shear stress response element and the Kruppel-like factor or KLF element. Previous in vitro studies suggested there're positive regulatory functions on flow induce transcription of the endothelial genes, including eNOS. However, the in-vivo function of these SIS DNA elements remains unknown. Dr. Carolyn Lam: Wow. So what did these investigators do, Greg? Dr. Greg Hundley: Right. So Carolyn the authors report for the first time that the shear stress response element and the KLF elements are critical flow sensors necessary for a transcriptionally permissive hypo methylated eNOS promoter in endothelial cells under chronic shear stress in vivo. Moreover endothelial nitric oxide synthase expression is regulated by flow dependent epigenetic mechanisms, which offers novel mechanistic insight on eNOS gene regulation in atherogenesis. Dr. Carolyn Lam: Nice. Thanks Greg. Well, let's go through what else is in this week's issue. In a cardiovascular case series, Dr. Ribeiro discusses the Platypnea-Orthodeoxia Syndrome, a case of persistent hypoxemia in an elderly patient. In ECG challenge, Dr. Challenge shows a case of diffuse St. Segment elevation with idiopathic malignant ventricular arrhythmias. There's an exchange of letters between doctors Wang and Sattler regarding the article cross priming dendritic cells exacerbate immunopathology after ischemic tissue damage in the heart. And there's an On My Mind article by Dr. Mullasari Sankardas on of occlusions, inclusions and exclusions time to reclassify infarctions. So interesting. Dr. Greg Hundley: Very nice, Carolyn. So I've got a couple of things in the mail bag. There is from Professor Kunfu a Research Letter entitled PTP MT-1 is required for embryonic cardio lipid biosynthesis to regulate mitochondrial morphogenesis and heart development. And then finally our own Bridget Kuhn has a cardiology news entitled vegan diets that are culturally aligned with traditional soul food gained popularity among black individuals. Well Carolyn, I can't wait to get to your feature discussion today. Dr. Carolyn Lam: Me too. Today's feature paper is about the impact of high deductible health plans on emergency department patients with non-specific chest pain and their subsequent care. I'm so pleased to have with us the first author Dr. Andrew Chou from Brigham and Women's hospital, as well as the editorialist Dr. Alexander Sandhu from Stanford university. Welcome gentlemen, please tell us about your current study. Dr. Andrew Chou: Yeah, so I think the reason we did this study was really obviously aware of the context, but also me working as an emergency decision. So anybody in the ED will now that, there's all kinds of versions of chest discomfort that comes through the ED and they always are worried about heart attack. And we do this testing kind of day in day out, it gets kind of inundated. So a lot of people have put thought into what we should do in the emergency room. We should get ECG, we should care cardiac enzymes when we're worried about it. But what really quite remains uncertain is really what to do afterwards. We get this patient, we test them, we didn't really find heart attacks, but there's a lot of uncertainty about what to do after. Do we do stress test, do we hospitalize them to get the stress test or other testing. Dr. Andrew Chou: As a result, there's a lot of variation in care. And I think partly because of that, they're kind of the shared decision making came out of that. As a part of the solution was to involve patient via, Hey, here are your risks. Let's talk about whether or not this would make sense for you to stay, get testing among other decisions. But what's always interesting to me is that even though we have this push towards having patients have kind of needing to make these decisions because of money, we don't really talk about costs and even their sort of sense of pride about, oh, we don't want to talk about costs. We just want to be the best medical treatment for you, but cost is such a reality for the patients. So, that's kind of the motivation behind getting this study done. So the way we wanted to test it was to set it up as closely as possible to run my trial but knowing that it's not really possible in the real world to do something like that. Dr. Andrew Chou: So we had to be pretty selective about who we include as a study population. So the first thing we did was we took essentially a large national insurer and their claims database. We look at only the people who enrolled in insurance products through their employer. So employers in the US can choose what type of plan they want to offer patients. And we only chose employers that offer only one type of insurance at a time within each year of a plan. So what we did is we chose people who had essentially two years of enrollment. And in the first year, they all have to have loaded up full plans. Dr. Andrew Chou: Meaning deductibles are less than $500. It's still a lot of money, but it's less compared to... The second year either they still have low deductible plan or the experimental group is going to be a group of people who employer only offer high deductible plan, which we define as having deductible greater than $1,000. So that sort of set up a control and experimental group with a similar baseline and then a different followup period of a year. And then we also did additional matching by employer characteristics and their own, the member characteristics to kind of make them as close as possible in terms of compabilities, age, as well as employer size, which we find to be a really big factor. Because large employers tend to have lower deductibles because they can risk care a lot better among their employees where a small employers like companies with five, 10 employees tend to have high deductible plans. So we use that population to compare essentially what happens after a certain company switch to kind of calculate the effect of the high deductible plan. Dr. Carolyn Lam: Great. Very novel design. But could you please tell us your results? Dr. Andrew Chou: Yeah, so we found is that once the employees from the companies that switch, there were less ED visits that ended up with a diagnosis of chest pain. This is important to bring in also the nuance here, which is that these are ED visits that effectively are not have been seen and test it. And they don't have a severe diagnosis like a heart attack or other significant cardiac issues that were found at least during the initial ED stay. And that decreased, which sort of makes the question whether or not these decreased visits or either where they just another chest visit without really other diagnoses or are they visits that actually have diagnosis. The other thing we found was also that there's a decrease in admissions from these ED visits actually. And majority of it, even though when we did our study, we actually were looking at admissions through the 30 days after these ED visits. Dr. Andrew Chou: But we found that the majority of difference is actually the admissions directly from these initial ED visits with time is just horrible. Two more things we found was that the amount of testing that was done after the ED visits, or not really consistently decreased because of high deductible, some tests really didn't have a difference and some more invasive and expensive tests did have some differences. But if you account for the decrease in the chest pain ED visits, then they're not really that notable. But the last finding, which perhaps is the most interesting of which is that there seems to be an increase in heart attack diagnosis and admissions after these visits for chest pain and our statistics for the entire study population actually wasn't significant. But we decided to look at the subgroup patients from poor communities who presumably have lower income and found that the same findings in this group was actually statistically consistent and so we felt comfortable reporting that. So I think that was probably the most interesting finding from our study. Dr. Carolyn Lam: Right. Thanks Andrew. Alex, I have to bring you in here. I really love the editorial love that you said to go or not to go as the title. But could you put these findings in context, please? Dr. Alexander Sandhu: Yes. Happy to and thank you for having me. I think studies like this study by Andrew and colleagues are incredibly important as we make health policy decisions that have large impacts on clinical decision-making for both patients and clinicians. It's important that we study them to understand how they impact patient decision-making clinical outcomes and costs, because obviously that can have important ramifications for future design at the end detecting unintended consequences. I think this study adds to a large body of work done by Andrew and his colleagues, really helping us to understand the implications of high deductible health plans on patient decision-making and subsequent outcomes. This is an incredibly important topic because of the proliferation of high deductible health plans over time and then potentially since the advent of the Affordable Care Act with fixed premiums leading to more and more cost sharing for patients. And it's really critical that we understand how that cost sharing impacts patients. Dr. Alexander Sandhu: And I think that chest pain is a wonderful test because chest pain can be something very serious. It's almost universal that when patients have acute onset chest pain, that a clinician asks them to go to the emergency department for further evaluation. However, we also have a large body of evidence that suggests that the large majority of chest pain episodes are not serious and don't end up needing additional treatment. So it's an area that I think both you could imagine decreased utilization once you applied cost sharing to patients. But what were you very much worried about the unintended consequences of people not going to the emergency department, if it's a serious condition. I think this was a well-designed quasi experimental analysis to look at the lower risk, but majority of episodes of chest pain where they're non-specific and not resulting in acute coronary syndrome and to try to demonstrate it that the high deductible health plans do lead to reductions in those episodes. Dr. Alexander Sandhu: I think as Andrew said, one of the most fascinating findings was this increase in acute MI's it was consistently significant amongst the low-income patients, but was not related to patients that were discharged because of potentially the effects of the high deductible and then came back in with acute MI's but were actually acute MI's during the initial admission. I was wondering if Andrew could maybe both explain that nuance a little bit more, which you get into the discussion of that paper, and then also walk us through maybe some thoughts that you and your study team had for causes for that potential finding. Dr. Andrew Chou: Yeah, absolutely. Thanks for raising that. So I think going into it initially, our hypothesis was really that, but when we first saw it, our initial thought was that, oh, maybe perhaps after they're discharged, they're supposed to get testing and patients or then follow up with their doctors. So they have increased poor outcomes. And so after that thought, that's when we did the kind of subgroup analysis looking at just patients who were discharged versus those who were admitted when they were diagnosed with chest pain at their initial ED visits. And exactly what we found is that the difference is really among people who were admitted initially, which is surprising to us. So I think what that signals to us is that our initial thought was not correct in the sense that this is not really a result of lack of followup or didn't intend to the testing that they were scheduled or didn't go see their doctor afterwards. But really like patients who are showing up in the ED already are more prone to perhaps having a heart attack. Dr. Andrew Chou: And so it really points to which is what you mentioned at your program, which we totally agree as well, that more upstream factors is affecting this. Could it be that they don't tend to take their medications as they should, or they didn't go to their doctors for checkups as they should, or they could have had earlier identification of heart problems if they have more perhaps milder symptoms beforehand until before the ED visits that could have presented certain things. So, that's hard to say. I do think that there is a... One of my mentors in this paper, Dr. Wareham, who has done a ton of work in the space of high deductible plan with kind of chronic disease management, they have definitely shown a lot of differences when patients have higher cost sharing. They'd certainly defer a lot of carriers, especially in diabetics have more complications and it might be a similar scenario here that which would make the most sense and fits the best with our findings here. Dr. Carolyn Lam: So that's a great question Alex and great insight Andrew. I think at this point, I need to ask you both. So what overall do you think is the clinical implication or there'd be any practical next step that you think should follow from this? Maybe I'll let Andrew start and then Alex finish? Dr. Andrew Chou: Sure. Thank you. I think there's kind of... I think two aspects to this one is really broader policy changes. I think if anything, it's quite uncertain whether or not the reduction in ED visits for chest pain is something detrimental. It's unsure whether or not the reduce admission is detrimental. But what is certain is that especially in lower income population certainly feels the higher out-of-pocket costs a lot more. And if there is an unintended consequence, it will certainly be magnified in this population. And in fact, I think a couple of past studies who having compared really high income versus low income population has found that really, high income patients tend to do okay and they're able to pick and choose appropriately of type of care they need. Whereas low-income patients tend to have really unanticipated changes. So, really trying to minimize the impact for low-income patients is going to be important policy direction. Dr. Andrew Chou: And there are a number of ways of doing it. I think there certainly is an increasing trend for companies to fund the health savings account, which is actually a tax deferred almost like investment accounts or certain fund to help them offset some of their healthcare out-of-pocket costs. But the other aspect of it, which I think is all a bit harder to push for is really for employers and insurance to just keeping their account patient's income when they're kind of pushing forward products for a high deductible plan. So low-income patients should just not have quite as big of a deductible as the high income earners do. But a different aspect it's really clinically for clinicians. It's tough because I think insurance put this forward because they want to influence patient decisions before they even see the clinician. But after they decide to come visit clinician, I think the clinician should be aware of the financial reality for the patient when making these decisions. Dr. Andrew Chou: But it's really hard for me to think about whether or not this is going to be a good thing for the patient or not. And one of the biggest concerns for really my colleagues in the department is really whether or not if we are really talking poor patients out of certain care by reviewing their financial reality with them and by through that are we essentially discriminating against other patients. So that's really a big unknown. I think that's definitely an area that we should definitely heavily invest in research because we're just pushing forward with price discussion for care to encourage price discussion at the clinic here without really knowing what's going to happen. Dr. Carolyn Lam: Yeah. Wow. Alex? Dr. Alexander Sandhu: Yeah, I definitely agree with Andrew. I think if we want to make decisions based on cost and we want patients to make those decisions and we as clinicians, obviously should be helping them. We need more transparency around costs, current deductible status, and that has to be available at the point of care so it actually can be integrated in decision-making. But I think that's likely not enough. I mean, even for clinicians, it's hard to determine how clinically necessary it is to get emergency evaluation before you see the patient when you get a phone call. So I think, if it's hard for clinicians with all of our years of experience, it's hard to understand how we can really expect that from our patients. Dr. Alexander Sandhu: I wholly agree with Andrew that I think a critical step is it's going to be important to reduce the risk of cost sharing for low-income patients with a number of potential interventions to do that, which I think are the real policy implications here. And then more generally, I think we should make sure that deductibles aren't discouraging utilization of high value cost effective intervention. There are currently safeguards in the Affordable Care Act about that. But I think we need to think about those closely and probably expand that so we don't see high deductible health plans leading to lower stat rates or worse diabetes prevention. Dr. Carolyn Lam: Wow. Words of wisdom. I just cannot thank you both enough for publishing such a beautiful paper, important findings, as well as just a very lovely editorial in Circulation. Thank you. Learned a lot. I'm sure the audience did too. Please remember you're listening to Circulation on the Run. Please tune in again next week with Greg and I. Dr. Greg Hundley: This program is copyright of the American heart association, 2021. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American heart association. For more visit ahajournals.org.  

Tune in for an interview with Philip Marsden in the first episode of our series dedicated to the Digital Markets Act (DMA) - the EU legislative proposal designed to complement existing competition law, in attempt to tame the power of digital platforms that, quoting the DMA itself, serve as a "gateway for business users to reach end users" - the so-called "gatekeepers".  Hear insights of Philip Marsden - who counts decades in various lead and advisory roles to competition enforcement and regulatory bodies as well as businesses - about why:He is a  proponents of 'running' with digital markets regulationDesignation as a 'gatekeeper' should not be appealableInstitutional design will be decisive for the DMA to succeedAnd many other ideas and suggestions he has on "restoring balance to digital competition".

Merriam-Webster's Word of the Day for May 7, 2021 is: archipelago • ahr-kuh-PEL-uh-goh • noun 1 : an expanse of water with many scattered islands 2 : a group of islands 3 : something resembling an archipelago; especially : a group or scattering of similar things Examples: "The Philippines, an archipelago of more than 7,100 islands, is recognized globally as a megadiverse nation and a biodiversity hotspot." — The Carnegie Museum of Natural History, 30 Mar. 2021 "For those who have the choice, an island is a place to go to simplify life, to strip it bare of the constant attention-battering of our world. When Francis was writing he was not to know that, by the time of publication, isolation would have left its island home to push us two metres apart, to make us archipelagos." — Philip Marsden, The Spectator, 3 Oct. 2020 Did you know? The Greeks called it the Aegean Pelagos and the Italians referred to it as Arcipelago (meaning "chief sea"), but English speakers now call it the Aegean Sea. Numerous islands dot its expanse, and 16th-century English speakers adopted a modified form of its Italian name for any sea with a similar scattering of islands. In time, archipelago came to refer to the groups of islands themselves, and now it is often used figuratively, as in, for example, "an archipelago of high-rise buildings."

The UK has approved a coronavirus vaccine and will start rolling it out. But what role does the media play in reporting the science, and perhaps even encouraging readers to take up the vaccine? Also in the programme, the government has announced a new Digital Markets Unit, a regulator of sorts that will look at Facebook and Google. Guests: Fiona Godlee, editor of the British Medical Journal, Laura Collins, editor of the Yorkshire Evening Post, Felicity Cross, deputy news editor of the Daily Star and Daily Star Sunday, and Philip Marsden, professor of law at the College of Europe. Studio engineer: John Boland Producer: Hannah Sander

19th November, 2020. Keynote Speaker: Philip Marsden, Author, Professor of Law and Economics, College of Europe, Belgium. Commentator: Simonetta Vezzoso, Professor of Competition Law, IP & Digital Policy, Università di Trento, Italy. Philip Marsden presents the study "Restoring Balance to Digital Competition – Sensible Rules, Effective Enforcement", wrote together with Rupprecht Podszun, with comments from Prof. Vezzoso.

    CROSTPATHS EXCITING NEW CROSSOVER CREW DETAIL EP PLANS & ANNOUNCE NEW SINGLE! Unstoppable alt-metal crew CROSTPATHS continue their ascension with the launch of their sophomore EP, Mutated, out Friday 27th November. Before then, the nu-metalcore rapscallions have just unleashed an explosive new single, Rampage, check out the single here https://youtu.be/JXqS2-d82iA Coming at you from Kent and born at the very end of 2018, CROSTPATHS made an early name for themselves with the release of last year's self-titled debut EP. Tracks from the record spawned radio airplay via Total Rock and Hard Rock Radio and grass roots support poured in from many quarters. Taking cues from Papa Roach, Fever 333, and Linkin Park, CROSTPATHS have managed to astutely etch fresh imprints on the nu-metalcore genre. Consisting of Ritchie Murray Jack (Lead Vox), Owain Lewis (Bass/Vox), Michael Edwards (Lead Guitars), and James Mason (Drums/Percussion), the emerging crew have recently signed to Enso Music Management  and have collaborated with local artists including Dohny Jep, WeatherView and apatternimperfect to produce remixes of their self-titled EP. Recently, the band's focus has firmly shifted to their thunderous new EP, Mutated. The record is a burly slice of alternative metal infused with killer breakdowns, monstrous riffs, rampant energy, and a plethora of hooks. Lead Vocalist, Ritchie Murray Jack remarks: "We wrote this high-octane material in late 2019 with the intention of a spring release to coincide with touring. Best laid plans eh? Sonically, it's all action, but lyrically the songs reflect a rollercoaster of emotions that many will be familiar with (especially now): anger, sorrow and stubborn defiance." CROSTPATHS have a hatful of blistering singles and videos on the way and will tour the EP as soon as the world allows. Stay tuned to their social sites for constant updates. https://www.youtube.com/channel/UCu8zEymgsw2XzmNroFgJtggs  https://www.facebook.com/crostpaths https://twitter.com/crostpaths https:open.spotify.com/artist/1UyQ9Us7cR1QggBbIcxxso  https://www.instagram.com/crostpaths/     My thoughts Rampage is a high energy track packed with monstrous riffs, a plethora of hooks, Crosspaths are not afraid to lay their cards on the table with this track and with a stunning breakdown in the middle of the track, it's a track that touches on so many great bands from the likes  of the Prodigy ,Hacktivist  Papa Roach and Fever 333. No doubt one we can all get back to being at live shows this is a track that will be a live fan favourite Not really knowing anything about the band I just feel this yet again is another band to keep eyes on because the beauty with music is anyone at anytime can pop up and showcase what they are about, if you ever hear people saying the scene is dead where is the next headliner for this festival, there are plenty of bands and artist out there some just need a platform and to be giving a chance to showcase what there about and just maybe Crosspaths are a band that could make the transition                       Following a strong 2019, London-based rock and roll three-piece Come at The King ar e due to release their second studio EP ‘Take To The Streets' on the 13th November.    Come At The King draw their influences from the blues-infused sounds of the early 00's garage rock revival, blended with the big riffs, hooking choruses and swagger of the mid 90's Britpop scene.    Inspired by the likes of Oasis and Arctic Monkeys, Take To The Streets - produced by Max Hopwood at London Road Studios and mastered by Philip Marsden, sees the band try to find the poetry in the mundane life of working-class towns in the shadow of big cities.   Very much a case of stick to what you know, the four-track EP explores the pursuit of romance, the tragic lives and small-mindedness of big egos in small towns and the unconditional admiration and respect of where you grew up.   Ahead of Take To The Streets' release, sees the release of it's leading single ‘In My Place' on the 6th November.    Take To The Streets is due for release November 13th and will be available on all major platforms.   COME AT THE KING ARE:   Max - Guitar, Vocals Cal - Drums Laurence - Bass       Facebook: https://www.facebook.com/comeatthekinguk Twitter: https://twitter.com/comeatthekinguk Instagram: https://www.instagram.com/comeatthekinguk/ Youtube https://www.youtube.com/channel/UC4y-Tl7mJ7qc65p9ohfEhSA Spotify:https://open.spotify.com/artist/36OMU7mJCoU0SHb9L3C1fm?si=qMhXOns2REepI48_38Q3fQ Apple Music: https://music.apple.com/us/artist/come-at-the-king/1446760565       My thoughts Take to the streets is a strong release from Come At The King the EP packed with big hooks and melodic tones, this is an ep that takes inspiration from the past rock legends such as oasis and the stone roses as well as cues from Morden day giants like Biffy Clyro and kings of Leon and as well as creating its own unique path for you to be taken guided down  overall this is tied up into a perfect packaged of production and well written songs my personal highlight is the track overgrown which I have included in the episode as this offers a great insight into the writing and production of the EP .  For fans of   The White Stripes Oasis The Charlatans The Stone Roses       You can find this episode and previous episodes from Setting The Tone in the below links Spotfiy https://open.spotify.com/show/6Jj9SsrXxve44839dptihN… Apple https://podcasts.apple.com/gb/podcast/setting-the-tone/id1499390718 Google https://podcasts.google.com/?q=setting%20the%20tone podbean https://Settingthetone2.podbean.com   Thank you to our sponsor @The Guitar Ninja Academy, the best place to become a guitar master. To get started the Guitar Ninja is offering 3 months for the price of 2 on membership for a limited time only hit the following link https://theguitarninja.co.uk/holidaydeals/   For more information our sponsor then hit the below links https://theguitarninja.co.uk https://www.facebook.com/theguitarninja      

Mark and Euan hear about the history and folklore connected to Philip's voyage.

In this episode of the CompCast – Competition Talks, Philip Marsden, Professor of Law and Economics at the College of Europe, shares his perspective on competition in the digital era.

Philip Marsden author of The Summer Isles, his single-handed voyage from the south coast of England round the west of Ireland & on to the northwest of Scotland in a small wooden sailing boat. Plus the Ireland Angling Show 2020 will be held at National Show Centre, Swords starting on 15th February, a 2 day event organised by Mara Media.

Philip Marsden is an English travel writer and novelist. He was elected as a Fellow of The Royal Society of Literature in 1996. He is a Trustee of the Royal Academy of Arts Development Trust.

Clare Balding walks with the writer Philip Marsden from his home near the banks of the River Fal out to the Cornish coastal path. Clare and Philip discuss why we react so strongly to certain places and why layers of stories and meaning build up around particular features in the landscape. Producer: Lucy Lunt.

Andrew Marr discusses why we react so strongly to some places, look for meaning in them and build up stories about them over time. Joining him in the studio are author and travel writer Philip Marsden who has been exploring Cornwall with Sense of Place in mind; Scottish artist Victoria Crowe who's been returning to paint the Pentland Hills for thirty years; singer Ian Bostridge who's performing and analysing Schubert's Winterreise; and lecturer Joanne Parker on the maps we make in our minds, as we draw together places that have the most meaning to us. Producer: Simon Tillotson.

Writing about place – a sub-genre of travel writing that subverts it by being about staying put, rather than moving – has been enjoying an extraordinary vogue of late. Three of the genre’s finest practitioners joined us at the shop to discuss its significance and future. Philip Marsden’s Rising Ground (Granta) explores the small part of Cornwall to which he has recently transplanted himself; Julian Hoffman, in The Small Heart of Things (Georgia) finds home around the shores of Greece's Prespa lakes, and Ken Worpole in The New English Landscape, a collaboration with the photographer Jason Orton (Field Station), proposes a new paradigm for topographical beauty based on the post-industrial landscape of the Thames estuary. The evening was hosted by Gareth Evans. See acast.com/privacy for privacy and opt-out information.

Sandi Toksvig meets novelist Richard Gwyn and translator Peter Bush to discuss Catalonia and its relationship with Spain. She hears how life is changing there, not just in the big city of Barcelona but in the more rural areas near the Pyrenees. Sandi also talks about the Cornish coast with the historian and author Philip Marsden who has lived in the Falmouth area for many years and reflects on the role of the sea in the lives of the residents and visitors from the days of sail to the present. Producer: Harry Parker.